MicroRNAs: new biomarker for diagnosis, prognosis, therapy prediction and therapeutic tools for acute lymphoblastic leukemia

  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract

    Back ground: MicroRNA (miRNA) was originally discovered in Caenorhabditis elegans by Victor Ambrose in 1993. It was predicted that miRNA account for 1-6% of the human genome and regulated at least 33% of protein-coding genes. Recently, 945 distinct miRNAs molecules have been identified within the human genome. It has been associated with the pathogenesis, progression and prognosis of different diseases, such as leukemia. MiR-181 family is one of those miRNA families, which generally expressed in 70 species and various human cancers.

    Objective: Assessment of mir-181a and LDH as promising co-biomarkers in order to provide additional information influence decisions about treatment sequentially to improve health outcomes of ALL in the Egyptian children.

    Patients and methods: This study was conducted on 100 children; 50 with ALL (38 males and 12 females) as ALL group. Other 50 healthy age and sex matched children were collected randomly as control group. Serum lactate dehydrogenase (LDH) and miRNA-181a were evaluated for all participants.

    Results: The results showed that there was a statistical significant difference between ALL and control groups regarding both molecular and biochemical indications of mir-181a and LDH were about almost five time as the control value, (P = 0.001). The ROC curve analysis revealed that the studied LDH and mir-181a markers were highly sensitive, highly specific and highly accurate test in the differentiation between the two studied ALL and control groups, with cutoff: ALL if mir-181a > 2.071, ALL if LDH > 0.307 respectively.

    Conclusion: MiRNA-181a and LDH can be used as co-biomarkers for ALL and might be beneficial in early diagnosis.



  • Keywords

    ALL; LDH; miRNA-181-a; Real Time-PCR; Leukemia.

  • References

      [1] Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. New England Journal of Medicine. 2015; 373 (16): 1541–1552. https://doi.org/10.1056/NEJMra1400972.

      [2] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer journal. 2017; 7(6): e577.‏ https://doi.org/10.1038/bcj.2017.53.

      [3] Payandeh M, Sadeghi E, Khodarahmi R, Sadeghi M. Appearance and disappearance of chronic myeloid leukemia (CML) in patient with chronic lymphocytic leukemia (CLL). International journal of hematology-oncology and stem cell research. 2014; 8(4): 49.‏

      [4] Liu R, Cao J, Gao X, Zhang J, Wang L, Wang B, Wang Z. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumor Biology. 2016; 37(10): 14083-14088.‏ https://doi.org/10.1007/s13277-016-5228-2.

      [5] Trzybulska D, Vergadi E, Tsatsanis C. miRNA and other non-coding RNAs as promising diagnostic markers. EJIFCC. 2018; 29(3): 221.‏

      [6] Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013; 152(6), 1237-1251.‏ https://doi.org/10.1016/j.cell.2013.02.014.

      [7] Younis A, Siddique MI, Kim CK, Lim KB. RNA interference (RNAi) induced gene silencing: a promising approach of hi-tech plant breeding. International journal of biological sciences. 2014; 10(10): 1150.‏ https://doi.org/10.7150/ijbs.10452.

      [8] Griffiths-Jones S, Bateman A, Marshall M, Khanna A, Eddy SR. Rfam: an RNA family database. Nucleic Acids Res. 2013; 31: 439–441. https://doi.org/10.1093/nar/gkg006.

      [9] Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011; 39: D152–157. https://doi.org/10.1093/nar/gkq1027.

      [10] Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334: 1351–1358. https://doi.org/10.1016/j.bbrc.2005.07.030.

      [11] Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011; 137: 557–566. https://doi.org/10.1007/s00432-010-0918-4.

      [12] Gao W, Yu Y, Cao H, Shen H, Li X. Deregulated expression of miR-21, miR-143 and miR-181a in non-small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010; 64: 399–408. https://doi.org/10.1016/j.biopha.2010.01.018.

      [13] Kaur P, Bartels CL, Bentley HA, Tsongalis GJ. Select microRNA profiles of patients with chronic lymphocytic Leukemia. Laboratory Investigation. 2011; 91: 450A.

      [14] Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2014; 129(7): 1401-1414. https://doi.org/10.1016/j.cell.2007.04.040.

      [15] Li Q, Liu L, Li W. Identifcation of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis. Tumour Biol. 2014; 35(10): 10467–10478. https://doi.org/10.1007/s13277-014-2364-4.

      [16] Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 2014; 21(5): 578-589. https://doi.org/10.1101/gad.1522907.

      [17] Cook L, Ng KW, Bagabag A, Corey L, Jerome KR. Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. Journal of clinical
      microbiology. 2004; 42(9):4130-4136. https://doi.org/10.1128/JCM.42.9.4130-4136.2004.

      [18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408. https://doi.org/10.1006/meth.2001.1262.

      [19] Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol, 2010; 84:1–16. https://doi.org/10.1111/j.1600-0609.2009.01348.x.

      [20] Ibrahim AS, Nazmi N. Cancer: The Growing Monster in Egypt. J Cancer Prev Curr Res. 2016; 6(4): 00217. https://doi.org/10.15406/jcpcr.2016.06.00217.

      [21] Lee JW, Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean journal of pediatrics. 2017; 60(5): 129.‏ https://doi.org/10.3345/kjp.2017.60.5.129.

      [22] Rana ZA, Rabbani MW, Sheikh MA, Khan AA. Outcome of childhood acute lymphoblastic leukaemia after induction therapy—3 years’ experience at a single paediatric oncology centre. Journal of Ayub Medical College Abbottabad. 2015; 21(4), 150-153.‏

      [23] El-Shafey AS, Amer SM, Allam NG, El-Alfy MS. Hematological studies in Egyptian children with Acute Lymphoid and Myeloid leukemia. Int. J. Adv. Biomed. 2017; 2(1): 19-29.

      [24] Jaime-Pérez, JC, García-Arellano G, Herrera-Garza JL., Marfil-Rivera LJ, Gómez-Almaguer, D. Revisiting the complete blood count and clinical findings at diagnosis of childhood acute lymphoblastic leukemia: 10-year experience at a single center. Hematology, transfusion and cell therapy. 2019; 41(1): 57-61.‏

      [25] Rasic I, Radovic S, Aksamija G. Relationship between chronic inflammation and the stage and histopathological size of colorectal carcinoma. Medical Archives. 2016; 70(2): 104.‏ https://doi.org/10.1016/j.htct.2018.05.010.

      [26] Starke ID, De Beer FC, Donnelly JP, Catovsky D, Goldman JM, Galton DA, Pepys MB. Serum C-reactive protein levels in the management of infection in acute leukaemia. European Journal of Cancer and Clinical Oncology. 2010; 20(3): 319-325.‏ https://doi.org/10.1016/0277-5379(84)90076-2.

      [27] Ishii E, Ueda K, Akazawa K, Nose Y. Fever in Children with Acute Leukemia: Cause and Role of Febrile Episode at Initial Diagnosis. Pediatric hematology and oncology. 2010; 7(1), 109-112.‏ https://doi.org/10.3109/08880019009034324.

      [28] Hafiz G, Mannan MA. Serum lactate dehydrogenase level in childhood acute lymphoblastic leukemia. Bangladesh Med Res Counc Bull. 2007; 33: 88-91. https://doi.org/10.3329/bmrcb.v33i3.1139.

      [29] Youssef AI, Ahmed MA, Samir M, Mansour IM, El Naggar MA, El Sewedy TS. Assessment of the Metabolic Mediators: Fatty Acid Synthase, Lactate Dehydrogenase and miR-181a as Potential Diagnostic Markers in Colorectal Cancer Patients. Bull. Egypt. Soc. Physiol. Sci. 2018; 38(1):1-12. https://doi.org/10.21608/besps.2018.8098.

      [30] Wang L, Liu X, Peng H, Xu L. The expression and functional study of miR-181a in pediatric acute lymphoblastic leukemia. Zhonghua xueyexue zazhi. 2015; 36(1), 53-57.‏




Article ID: 29429
DOI: 10.14419/ijbr.v7i1.29429

Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.